Satellos Bioscience Inc. (TSX:MSCL)

Canada flag Canada · Delayed Price · Currency is CAD
1.070
+0.130 (13.83%)
Jan 22, 2026, 3:57 PM EST
20.22%
Market Cap174.38M
Revenue (ttm)n/a
Net Income (ttm)-30.04M
Shares Out185.51M
EPS (ttm)-0.19
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume518,261
Average Volume261,218
Open0.920
Previous Close0.940
Day's Range0.920 - 1.080
52-Week Range0.520 - 1.070
Beta0.71
RSI71.23
Earnings DateMar 26, 2026

About Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British C... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 17
Stock Exchange Toronto Stock Exchange
Ticker Symbol MSCL
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements